Milestone Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Regulatory and Corporate Update
Portfolio Pulse from
Milestone Pharmaceuticals has reported its third quarter 2024 financial results and provided updates on its regulatory and corporate activities. The New Drug Application (NDA) for CARDAMYST™ in paroxysmal supraventricular tachycardia (PSVT) is currently under review by the FDA, with a Prescription Drug User Fee Act (PDUFA) date set for March 27, 2025.
November 12, 2024 | 2:15 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Milestone Pharmaceuticals' NDA for CARDAMYST™ in PSVT is under FDA review, with a PDUFA date of March 27, 2025. This regulatory milestone is crucial for the company's future prospects.
The NDA review and upcoming PDUFA date are significant events for Milestone Pharmaceuticals, as approval could lead to market entry and potential revenue growth. The stock may see positive movement as the PDUFA date approaches, reflecting investor anticipation.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100